CN1273832A - Compound Yexiazhu medicine and preparing process thereof - Google Patents
Compound Yexiazhu medicine and preparing process thereof Download PDFInfo
- Publication number
- CN1273832A CN1273832A CN 00107304 CN00107304A CN1273832A CN 1273832 A CN1273832 A CN 1273832A CN 00107304 CN00107304 CN 00107304 CN 00107304 A CN00107304 A CN 00107304A CN 1273832 A CN1273832 A CN 1273832A
- Authority
- CN
- China
- Prior art keywords
- yexiazhu
- medicine
- radix
- compound
- described compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
A compound Yexiazhu medicine for nourishing Qi and spleen, improving immunity and microcirculation, resisting against virus and liver fibrosis, and detoxication is prepared from 9 Chinese-medicinal materials including Yexiazhu, astragalus root, gymstemma pentaphyllum, white atractylodes rhizome, etc.
Description
The present invention relates to a kind of compound Yexiazhu medicine and preparation method thereof, belong to prepared from traditional Chinese medicines product and fabricating technology field thereof.
Chronic hepatitis B is a kind of commonly encountered diseases and frequently-occurring disease, can develop into liver cirrhosis or hepatocarcinoma as untimely treatment, serious harm health, and existing treatment chronic hepatitis B is based on Western medicine, but curative effect is not satisfactory.
The purpose of this invention is to provide a kind of is primary raw material with the Chinese herbal medicine Cacumen Securinegae Suffruticosae, can effectively suppress hepatitis B virus duplication, improves compound Yexiazhu medicine of curative effects such as liver function and anti-hepatic fibrosis and preparation method thereof.
The present invention is a compound Yexiazhu medicine, and its primary raw material comprises Cacumen Securinegae Suffruticosae, the Radix Astragali, Herb Gynostemmae Pentaphylli, the Rhizoma Atractylodis Macrocephalae, Herba Sedi, Herba Artemisiae Scopariae, Radix Paeoniae Rubra, Radix Salviae Miltiorrhizae, Radix Curcumae etc., the percentage by weight that it is characterized in that each component is: Cacumen Securinegae Suffruticosae 30～45%, the Radix Astragali 4～10%, Herb Gynostemmae Pentaphylli 3～7%, the Rhizoma Atractylodis Macrocephalae 3～7%, Herba Sedi 7～13%, Herba Artemisiae Scopariae 8～22%, Radix Paeoniae Rubra 4～10%, Radix Salviae Miltiorrhizae 4～10%, Radix Curcumae 3～7%.Cold in nature, the bitter in the mouth of described Cacumen Securinegae Suffruticosae, energy heat-clearing and toxic substances removing, removing food stagnancy make eye bright, and can control carbuncle
, snakebite and infantile malnutrition; The described Radix Astragali is warm in nature, and the energy invigorating the spleen and replenishing QI can be controlled various deficiency syndrome; Described Herb Gynostemmae Pentaphylli is flat, and the blood fat reducing of reducing phlegm can be controlled various hyperlipemias; The described Rhizoma Atractylodis Macrocephalae is warm in nature, and energy the spleen strengthening and damp drying diuretic can be controlled various edema due to deficiency of the spleen, dyspepsia; Described Herba Sedi is cool in nature, can heat-clearing and toxic substances removing dampness removing, but the scorching sore for the treatment of the liver, Serpentis are hindered; Described Herba Artemisiae Scopariae cold nature, energy heat-clearing and dampness-resolving, the subcutaneous ulcer of can harnessing the Yellow River hepatitis; Described Radix Paeoniae Rubra cold nature can be invigorated blood circulation by clearing away heat and cooling blood, can control the disease of various blood stasis; Described Radix Salviae Miltiorrhizae cold nature can be invigorated blood circulation, be allayed excitement, and can control various Blood stasis; Described Radix Curcumae cold nature can promoting QI circulation for relieving depression be drawn together blood, short gallbladder hidropoiesis, and the promoting the function of the gallbladder to alleviate jaundice fossil can be controlled the epidemic febrile disease heat-blockage, coma.Compound Yexiazhu medicine energy replenishing QI to invigorate the spleen, detoxifcation by the said herbal medicine preparation invigorated blood circulation, the dampness removing jaundice eliminating, has comprehensive therapeutic effects such as the immunologic function of raising, antiviral, microcirculation improvement and anti-hepatic fibrosis.
Described Cacumen Securinegae Suffruticosae can be the ripe Phyllanthusamarus of Shaoxing, Zhejiang Province Guiji Shan Mountain bamboo trunk growth.Also can add Fructus Crataegi in the described compound Yexiazhu medicine, Radix Glycyrrhizae etc., its addition can be by weight percentage: Fructus Crataegi 1～3%, Radix Glycyrrhizae 1～3%, Fructus Crataegi slightly warm in nature, the stagnant regulating qi to disperse stagnation that can disappear, blood fat reducing; Radix Glycyrrhizae property is flat, energy supplementing QI for promoting the production of body fluid and middle emergency, the mediation property of medicine.Energy relieving dyspepsia blood fat reducing improves and takes effect.
The preparation method of described compound Yexiazhu medicine is: all raw materials by weight metering backs are mixed, decoct with water secondary, and collecting decoction concentrates then, after leaving standstill at 36～48 o'clock, draw supernatant liquid filtering, with filtrate with the sucrose heating for dissolving, sterilization filling after filtering at last.Described compound Yexiazhu medicine can be liquid electuary or powdery capsule.Described with after the sucrose heating for dissolving, also can add antiseptic ethyl hydroxybenzoate and sodium benzoate.
It is that principal agent cooperates the Radix Astragali, Herb Gynostemmae Pentaphylli etc. to make compound granules or powder that the present invention adopts Cacumen Securinegae Suffruticosae; make it to bring into play its drug synergism preferably from the pharmacological function of multiple spot position; after patient takes; can effectively suppress the virus replication effect; reduce liver inflammation degree and protect impaired hepatocellular reparation; through clinical practice and paired observation, have the inhibition hepatitis B virus duplication, improve curative effects such as liver function and anti-hepatic fibrosis.
Below in conjunction with embodiment the present invention is further described:
Compound Yexiazhu medicine embodiment of the present invention can name and be " cornea liver treasured " oral liquid
One, prescription is formed: (being weight percentage in the bracket)
Cacumen Securinegae Suffruticosae 600～800 gram (30～40%) Radix Astragali 100～200 grams (5～10%)
The Rhizoma Atractylodis Macrocephalae 80～120 gram (4～6%) Herba Sedis 150～250 grams (7～12%)
Herba Artemisiae Scopariae 200～400 gram (10～20%) Radix Paeoniae Rubra 100～200 grams (5～10%)
Radix Salviae Miltiorrhizae 100～200 gram (5～10%) Herb Gynostemmae Pentaphyllis 80～120 grams (4～6%)
Radix Curcumae 80～120 gram (4～6%) Fructus Crataegi 40～60 grams (2～3%)
An amount of ethyl hydroxybenzoate 0.8～1.2 gram of Radix Glycyrrhizae 40～60g (2～3%) sucrose
Sodium benzoate 2～3 grams
Two, preparation technology
Get the recipe quantity medical material clean put → decoct with water secondary → collecting decoction in order and be concentrated in right amount → leave standstill 48 hours → absorption supernatant liquid filtering → filtrate is with sucrose heating for dissolving → adding preservative agent (ethyl hydroxybenzoate and sodium benzoate) → fill → seal → sterilize → quality inspection → packing
Three, clinical data
1, object: select HBsAg (surface antigen), HBeAg (E antigen), anti--all male chronic hepatitis B patient 192 examples of HBc (core antibody), diagnosis meet nineteen ninety-five Beijing infectious disease and the parasitic disease academic conference formulate standard.Be divided into treatment at random and organize 100 examples: slight 49 examples, moderate 46 examples, severe 5 examples.The course of disease 1～7 year reaches 15 years most, middle male 71 examples, women 29 examples, 8～58 years old age, average 32 years old.Matched group 92 examples: slight 45 examples, moderate 41 examples, severe 6 examples.The course of disease 1～7 year, wherein male 64 examples, women 28 examples, 9～60 years old age, average 33 years old.Two groups of clinical datas have comparability.
2, the instructions about how to take medicine and the course of treatment: the treatment group is taken this medicine oral medicine 30ml at every turn, and three times on the one, two months is the course of treatment.Matched group is taken conventional hepatinica such as inosine, glucuronolatone, vitamins etc., is the course of treatment with two months also.Two groups all do not add and use other antiviral agents during the treatment.
3, observation item and standard: 1. three of hepatitis B virus standards (HBsAg, HBeAg, HBV-DNA) are before treatment, and finish the course of treatment and drug withdrawal detected during half a year, decide the positive and turn out cloudy to effectively.2. liver function (ALT, TBiL and A/G) and hepatic fibrosis sign projects such as (HA, CIV) are done contrast and are detected before treatment, when finish the course of treatment.Deciding ALT, TBiL and A/G serves as effective to recover normal (multiple normal).
4, statistical procedures; The present embodiment data are all handled (mainly using checks such as x, t value) by number reason method.
Four, result
1, hepatitis b virus marker changes (as shown in table 1): treatment group serum HBeAg (E antigen) negative conversion rate when finish the course of treatment and drug withdrawal be respectively 58.0% and 49.0% during half a year, matched group is respectively 15.0% and 11.9%; Treatment group HBV-DNA (hepatitis B virus---DNA (deoxyribonucleic acid)) negative conversion rate is respectively 46.0% and 40.7%, and matched group is respectively 13.2% and 11.1%, above-mentioned two comparisons, and there were significant differences (P＜0.05) than matched group for the treatment group.
2, changes of liver function (as shown in table 2): through a course of treatment control finish after, the normalization rate of treatment group and control group A LT (glutamate pyruvate transaminase) is respectively 80.0% (80/100) and 51.07% (47/92); The normalization rate of TBiL (serum total bilirubin) is respectively 71.4% (40/56) and 45.5% (25/55); The normalization rate of A/G (albumins/globulins) ratio is respectively 65.1% (28/43) and 30.9% (13/42), and two groups relatively, and the liver function recovery effect of treatment group is obviously than matched group remarkable (P＜0.05)
3, the hepatic fibrosis sign changes (as shown in table 3): treatment organize finish back HA (hyaluronic acid) and CIV (four Collagen Type VIs) the course of treatment fall obviously greater than matched group, its significant difference (P＜0.05).Table 1: serum hepatitis B virus index change-detection time group HBsAg HBeAg HBV-DNA
Treatment organizes 0/,100 0 0/,100 0 0,/54 0 before (changeing one) % (changeing) % (changeing) % P treatment
Matched group finishes treatment and organize 8/,100 8.0 58/,100 58.0 26,/54 46.0 0,/92 0 0,/92 0 0,/53 0 course of treatment
＜0.05
Matched group 1,/92 1.09 14,/92 15.2 7,/53 13.2 drug withdrawal during half a year treatment organize 7/,100 7.0 49/,100 49.0 22,/54 40.7
＜0.05
Matched group 2,/92 2.16 11,/92 11.9 6,/53 11.1
Table 2: change the normal again normalization rate PALT treatment of project group example number when finishing the course of treatment before the liver function treatment and organize 100 80/,100 80.0
＜0.05
Matched group 92 47/92 51.07TBiL treatments organize 56 40,/56 71.4
＜0.05
Matched group 55 25/55 45.5A/G treatments organize 43 28,/43 65.1
＜0.05
Matched group 42 13,/42 30.9
Table 2: change before and after hepatic fibrosis sign HA, the CIV treatment
X ± s project group example number
Control back PHA treatment before controlling and organize 100 204.55 ± 83.15 103.15 ± 45.83＜0.05
Matched group 92 202.31 ± 81.76 171.28 ± 52.12 0.05CIV treatments organize 100 83.08 ± 39.33 56.12 ± 28.31＜0.05
Matched group 92 82.76 ± 38.46 71.03 ± 30.17 0.05
Annotate: normal parameter HA:57 ± 27mg/ml CIV:49.77 ± 15mg/ml.
Five, discuss:
1, this research application Phyllanthusamarus is that principal agent cooperates Chinese herbal medicine such as the Radix Astragali, make compound recipe Phyllanthusamarus treatment chronic hepatitis B, take that finish a course of treatment and drug withdrawal during half a year the HBeAg negative conversion rate be respectively 58.0% and 49.0%, and the matched group negative conversion rate is respectively 13.2% and 11.1%, two groups there were significant differences (P＜0.05), illustrates that it has the effect of the virus replication of inhibition.And the prompting compound preparation to use Phyllanthusamarus one medicine more separately be excellent, this is owing to add Chinese medicine medicines such as the Radix Astragali, Herb Gynostemmae Pentaphylli in the compound recipe Phyllanthusamarus prescription element, according to the multicomponent characteristics of compound recipe, bring into play its drug synergism preferably from the pharmacological function of multiple spot position.
2, treatment group clinical observation result, it reduces ALT and TBiL and improves A/G ratio than matched group remarkable (every P all＜0.05), shows that the compound recipe Phyllanthusamarus has reduction liver inflammation program and protects impaired hepatocellular reparation, improves the curative effect of liver function.
3, the variation of serum HA, CIV level can reflect the degree of hepatic fibrosis preferably, is the good sign of diagnosing liver fibrosis.There were significant differences (P＜0.05) than matched group in the decline of treatment group serum HA and CIV amplitude.Show that clinical practice compound recipe Phyllanthusamarus can alleviate degree of hepatic fibrosis, has effect of anti hepatic fibrosis.
In sum, compound recipe Phyllanthusamarus medicament has the hepatitis B virus duplication of inhibition, improves curative effects such as liver function and anti-hepatic fibrosis through the clinical application research result.In addition, select the ripe Phyllanthusamarus of Shaoxing, Zhejiang Province Guiji Shan Mountain bamboo trunk growth for use, because this area's particular climate and edaphic condition are compared with the Cacumen Securinegae Suffruticosae that other areas produce, its curative effect is particularly evident.
Claims (6)
1, a kind of compound Yexiazhu medicine, its raw material comprises Cacumen Securinegae Suffruticosae, the Radix Astragali, Herb Gynostemmae Pentaphylli, the Rhizoma Atractylodis Macrocephalae, Herba Sedi, Herba Artemisiae Scopariae, Radix Paeoniae Rubra, Radix Salviae Miltiorrhizae, Radix Curcumae, the percentage by weight that it is characterized in that each component is: Cacumen Securinegae Suffruticosae 30～45%, the Radix Astragali 4～10%, Herb Gynostemmae Pentaphylli 3～7%, the Rhizoma Atractylodis Macrocephalae 3～7%, Herba Sedi 7～13%, Herba Artemisiae Scopariae 8～22%, Radix Paeoniae Rubra 4～10%, Radix Salviae Miltiorrhizae 4～10%, Radix Curcumae 3～7%.
2,, it is characterized in that described Cacumen Securinegae Suffruticosae can be the ripe Phyllanthusamarus of Shaoxing, Zhejiang Province Guiji Shan Mountain bamboo trunk growth by the described compound Yexiazhu medicine of claim 1.
3, by the described compound Yexiazhu medicine of claim 1, it is characterized in that also can adding Fructus Crataegi in the described medicament, Radix Glycyrrhizae, its addition can be by weight percentage: Fructus Crataegi 1～3%,, Radix Glycyrrhizae 1～3%.
4, by claim 1 or 2, the preparation method of 3 described compound Yexiazhu medicines, it is characterized in that: all raw materials by weight metering backs are mixed, decoct with water secondary, collecting decoction concentrates then, leave standstill at 36～48 o'clock after, draw supernatant liquid filtering, with filtrate with the sucrose heating for dissolving, sterilization filling after filtering at last.
5, by claim 1 or 2,3 described compound Yexiazhu medicines, it is characterized in that described compound Yexiazhu medicine can be liquid electuary or powdery capsule.
6, by the preparation method of the described compound Yexiazhu medicine of claim 4, it is characterized in that described with also adding antiseptic ethyl hydroxybenzoate and sodium benzoate after the sucrose heating for dissolving.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00107304A CN1112194C (en) | 2000-05-09 | 2000-05-09 | Compound yexiazhu medicine and preparing process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00107304A CN1112194C (en) | 2000-05-09 | 2000-05-09 | Compound yexiazhu medicine and preparing process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1273832A true CN1273832A (en) | 2000-11-22 |
| CN1112194C CN1112194C (en) | 2003-06-25 |
Family
ID=4578607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN00107304A Expired - Fee Related CN1112194C (en) | 2000-05-09 | 2000-05-09 | Compound yexiazhu medicine and preparing process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1112194C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028374B (en) * | 2007-01-15 | 2011-05-04 | 广西中医学院 | Chinese-medicinal preparation for treating liver diseases and its preparation method and use |
| CN102406906A (en) * | 2011-11-22 | 2012-04-11 | 荣成市交通诊所 | Traditional Chinese medicine composition for treating acute hepatitis B |
| CN103211999A (en) * | 2013-05-03 | 2013-07-24 | 南京中医药大学 | Controlled-release pellet for treating acute and chronic hepatitis and preparation method and application thereof |
| CN104623531A (en) * | 2015-01-12 | 2015-05-20 | 白忠可 | Heat-clearing and damp expelling traditional Chinese medicine medicament for chronic active hepatitis and preparation method |
| CN106038684A (en) * | 2016-06-28 | 2016-10-26 | 江苏省农业科学院 | Traditional Chinese herbal medicine compound for preventing and treating porcine circovirus disease, as well as preparation method and application thereof |
| CN115607647A (en) * | 2022-11-11 | 2023-01-17 | 森隆药业有限公司 | Application of Anluo chemical fiber composition in preparing anti-fibrosis drugs |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1063954C (en) * | 1997-04-03 | 2001-04-04 | 周道红 | Chinese patent medicine-powder preparation for curing hepatitis B |
-
2000
- 2000-05-09 CN CN00107304A patent/CN1112194C/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028374B (en) * | 2007-01-15 | 2011-05-04 | 广西中医学院 | Chinese-medicinal preparation for treating liver diseases and its preparation method and use |
| CN102406906A (en) * | 2011-11-22 | 2012-04-11 | 荣成市交通诊所 | Traditional Chinese medicine composition for treating acute hepatitis B |
| CN103211999A (en) * | 2013-05-03 | 2013-07-24 | 南京中医药大学 | Controlled-release pellet for treating acute and chronic hepatitis and preparation method and application thereof |
| CN103211999B (en) * | 2013-05-03 | 2014-07-16 | 南京中医药大学 | Controlled-release pellet for treating acute and chronic hepatitis and preparation method and application thereof |
| CN104623531A (en) * | 2015-01-12 | 2015-05-20 | 白忠可 | Heat-clearing and damp expelling traditional Chinese medicine medicament for chronic active hepatitis and preparation method |
| CN106038684A (en) * | 2016-06-28 | 2016-10-26 | 江苏省农业科学院 | Traditional Chinese herbal medicine compound for preventing and treating porcine circovirus disease, as well as preparation method and application thereof |
| CN115607647A (en) * | 2022-11-11 | 2023-01-17 | 森隆药业有限公司 | Application of Anluo chemical fiber composition in preparing anti-fibrosis drugs |
| CN115607647B (en) * | 2022-11-11 | 2024-02-02 | 森隆药业有限公司 | Application of Anluo chemical fiber composition in preparation of anti-fibrosis drugs |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1112194C (en) | 2003-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1692939A (en) | Traditional Chinese medicine pill for treating hepatitis B, and its prepn. method | |
| CN1062157C (en) | Hepatitis B curing toxin-dissipating pill | |
| CN1268355A (en) | Yichanmanshenkang medicine for curing nephroses | |
| CN1112194C (en) | Compound yexiazhu medicine and preparing process thereof | |
| CN1698812A (en) | Pharmaceutical composition for treating hepatitis B | |
| CN1052889C (en) | Chinese proprietary for curing hepatitis | |
| CN1066628C (en) | Medicine for chronic hepatitis B and its preparation | |
| CN1063954C (en) | Chinese patent medicine-powder preparation for curing hepatitis B | |
| CN1386546A (en) | Capsule 'Yibao Yishou' for elongating life | |
| CN105902888A (en) | Traditional Chinese medicine decoction for treating infantile acute nephritis | |
| CN1294980C (en) | Medicine for treating liver disease | |
| CN1319586C (en) | Medicinal composition for treating brain apoplexy | |
| CN1481876A (en) | Medication for virus hepatitis and hepatocirrhosis | |
| CN1059117C (en) | Katsutoxin pill for tumor and preparing method thereof | |
| CN1054075C (en) | Chinese medicine 'Xiaoyangtang' for curing acute and chronic hepatitis B | |
| CN100441210C (en) | Compound for mula preparation for treating chronic hepatitis B virus and its preparation method | |
| CN103272145B (en) | Traditional Chinese medicinal composition for treating oral lichen planus and application | |
| CN1085548C (en) | Traditional Chinese medicinal prepns. for treating hepatitis B virus, and method for preparing same | |
| CN1340353A (en) | Orally-applied medicine for treating hepatism and its preparing process | |
| CN1233340C (en) | Chinese medicine dialysate for maintenance hemodialysis of chronic renal failure, and preparing method thereof | |
| CN1864728A (en) | Prescription and preparation method of yin-nourishing capsule containing ginseng and astragalus root | |
| CN1106856C (en) | Hepatosis treating medicine and its preparation | |
| CN1062765C (en) | Jaundice diminishing medicine good for liver | |
| CN1086949C (en) | Chinese medicine for hepatitis B and its preparation | |
| CN1058404C (en) | Hepatitis B treating medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |